Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| 1 |
NVIDIA
NVDA
|
+$1B |
| 2 |
Netflix
NFLX
|
+$721M |
| 3 |
Apple
AAPL
|
+$468M |
| 4 |
UnitedHealth
UNH
|
+$422M |
| 5 |
GE Vernova
GEV
|
+$376M |
Top Sells
| 1 |
Broadcom
AVGO
|
+$673M |
| 2 |
Robinhood
HOOD
|
+$481M |
| 3 |
Meta Platforms (Facebook)
META
|
+$433M |
| 4 |
Alphabet (Google) Class A
GOOGL
|
+$402M |
| 5 |
Palantir
PLTR
|
+$380M |
Sector Composition
| 1 | Technology | 19.67% |
| 2 | Healthcare | 15.34% |
| 3 | Consumer Discretionary | 12.38% |
| 4 | Financials | 11.51% |
| 5 | Industrials | 8.92% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
3176
Marti Technologies
MRT
$189M
| $195K | ﹤0.01% |
64,500
+45,412
| +238% | +$138K |
|
|
TBI
3177
Trueblue
TBI
$165M
| $194K | ﹤0.01% |
+29,900
| New | +$194K |
|
3178
IO Biotech
IOBT
$119M
| $194K | ﹤0.01% |
139,300
+12,900
| +10% | +$17.9K |
|
3179
Rhinebeck Bancorp
RBKB
$144M
| $194K | ﹤0.01% |
+16,500
| New | +$194K |
|
3180
SPAR Group
SGRP
$28M
| $193K | ﹤0.01% |
201,300
-6,285
| -3% | -$6.03K |
|
3181
Cabaletta Bio
CABA
$150M
| $192K | ﹤0.01% |
126,100
+115,200
| +1,057% | +$175K |
|
3182
Minerva Neurosciences
NERV
$15M
| $191K | ﹤0.01% |
111,000
-3,097
| -3% | -$5.33K |
|
3183
Apellis Pharmaceuticals
APLS
$3.39B
| $190K | ﹤0.01% |
+10,988
| New | +$190K |
|
3184
Enlivex Therapeutics
ENLV
$24.6M
| $189K | ﹤0.01% |
168,392
-12,897
| -7% | -$14.4K |
|
3185
Comstock
LODE
$120M
| $188K | ﹤0.01% |
49,508
-15,300
| -24% | -$58K |
|
3186
Cocrystal Pharma
COCP
$14.9M
| $186K | ﹤0.01% |
125,028
-600
| -0.5% | -$894 |
|
3187
Brilliant Earth
BRLT
$38.1M
| $185K | ﹤0.01% |
134,600
+1,800
| +1% | +$2.48K |
|
|
JBS
3188
JBS N.V.
JBS
$34.6B
| $181K | ﹤0.01% |
+12,538
| New | +$181K |
|
|
FGNX
3189
Fundamental Global
FGNX
$9.91M
| $180K | ﹤0.01% |
11,231
-300
| -3% | -$4.8K |
|
3190
Better Home & Finance Holding
BETR
$372M
| $179K | ﹤0.01% |
+14,452
| New | +$179K |
|
3191
Sportsman's Warehouse
SPWH
$115M
| $179K | ﹤0.01% |
51,800
-297,700
| -85% | -$1.03M |
|
3192
NSTS Bancorp
NSTS
$61.9M
| $178K | ﹤0.01% |
14,400
| – | – |
|
|
RAPP
3193
Rapport Therapeutics
RAPP
$1.02B
| $177K | ﹤0.01% |
+15,600
| New | +$177K |
|
3194
Zenvia
ZENV
$81.3M
| $177K | ﹤0.01% |
118,201
-15,000
| -11% | -$22.5K |
|
3195
Metagenomi
MGX
$69.8M
| $176K | ﹤0.01% |
119,000
+19,400
| +19% | +$28.7K |
|
3196
Celcuity
CELC
$2.58B
| $175K | ﹤0.01% |
+13,100
| New | +$175K |
|
3197
Quantum-Si Incorporated
QSI
$233M
| $175K | ﹤0.01% |
89,200
-782,556
| -90% | -$1.53M |
|
3198
Dare Bioscience
DARE
$29.1M
| $172K | ﹤0.01% |
71,795
+1,200
| +2% | +$2.87K |
|
|
AHG
3199
Akso Health Group
AHG
$1.03B
| $170K | ﹤0.01% |
130,798
-14,400
| -10% | -$18.7K |
|
3200
Outlook Therapeutics
OTLK
$41.2M
| $170K | ﹤0.01% |
+106,068
| New | +$170K |
|